Inhibitors of protein tyrosine phosphatases

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Protein tyrosine phosphatases (PTPs) are a large family of enzymes whose structural diversity and complexity rival those of protein tyrosine kinases (PTKs). This chapter summarizes and updates what is currently known about PTP inhibitors. Both specific and non-specific small molecule competitive and reversible PTP inhibitors are discussed. In addition, some examples of covalent and time-dependent PTP inactivators are also presented. Although all PTPs share a common catalytic mechanism and catalyze the same biochemical reaction, the hydrolysis of phosphoamino acids, they have distinct (and often unique) biological functions in vivo. Genetics and biochemical studies indicate that PTPs are involved in a number of disease processes. In spite of the large number of PTPs identified to date, and the emerging roles played by PTPs in human diseases, a detailed understanding of the role played by PTPs in normal physiology and in pathogenic conditions has been hampered by the absence of PTP-specific agents. Such PTP specific inhibitors could potentially serve as useful tools in determining the physiological significance of protein tyrosine phosphorylation in complex cellular signal transduction pathways, and may constitute valuable therapeutics in the treatment of several human diseases. Significant differences exist within the active site and its immediate surroundings of various PTPs, such that selective, tight-binding PTP inhibitors can be developed. Combinatorial solid-phase library synthesis is finding wide applicability throughout the pharmaceutical industry and has begun to yield fruitful results in the area of PTP inhibitors.

Original languageEnglish
Title of host publicationHandbook of Cell Signaling, 2/e
PublisherElsevier Inc.
Pages727-735
Number of pages9
Volume2
ISBN (Print)9780123741455
DOIs
StatePublished - 2010

Fingerprint

Protein Tyrosine Phosphatases
Phosphoamino Acids
Signal transduction
Solid-Phase Synthesis Techniques
Phosphorylation
Physiology
Drug Industry
Protein-Tyrosine Kinases
Tyrosine
Molecular Biology
Hydrolysis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Zhang, Z-Y. (2010). Inhibitors of protein tyrosine phosphatases. In Handbook of Cell Signaling, 2/e (Vol. 2, pp. 727-735). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-374145-5.00093-0

Inhibitors of protein tyrosine phosphatases. / Zhang, Zhong-Yin.

Handbook of Cell Signaling, 2/e. Vol. 2 Elsevier Inc., 2010. p. 727-735.

Research output: Chapter in Book/Report/Conference proceedingChapter

Zhang, Z-Y 2010, Inhibitors of protein tyrosine phosphatases. in Handbook of Cell Signaling, 2/e. vol. 2, Elsevier Inc., pp. 727-735. https://doi.org/10.1016/B978-0-12-374145-5.00093-0
Zhang Z-Y. Inhibitors of protein tyrosine phosphatases. In Handbook of Cell Signaling, 2/e. Vol. 2. Elsevier Inc. 2010. p. 727-735 https://doi.org/10.1016/B978-0-12-374145-5.00093-0
Zhang, Zhong-Yin. / Inhibitors of protein tyrosine phosphatases. Handbook of Cell Signaling, 2/e. Vol. 2 Elsevier Inc., 2010. pp. 727-735
@inbook{5cfa167f4b444dc883974f8d9d741aac,
title = "Inhibitors of protein tyrosine phosphatases",
abstract = "Protein tyrosine phosphatases (PTPs) are a large family of enzymes whose structural diversity and complexity rival those of protein tyrosine kinases (PTKs). This chapter summarizes and updates what is currently known about PTP inhibitors. Both specific and non-specific small molecule competitive and reversible PTP inhibitors are discussed. In addition, some examples of covalent and time-dependent PTP inactivators are also presented. Although all PTPs share a common catalytic mechanism and catalyze the same biochemical reaction, the hydrolysis of phosphoamino acids, they have distinct (and often unique) biological functions in vivo. Genetics and biochemical studies indicate that PTPs are involved in a number of disease processes. In spite of the large number of PTPs identified to date, and the emerging roles played by PTPs in human diseases, a detailed understanding of the role played by PTPs in normal physiology and in pathogenic conditions has been hampered by the absence of PTP-specific agents. Such PTP specific inhibitors could potentially serve as useful tools in determining the physiological significance of protein tyrosine phosphorylation in complex cellular signal transduction pathways, and may constitute valuable therapeutics in the treatment of several human diseases. Significant differences exist within the active site and its immediate surroundings of various PTPs, such that selective, tight-binding PTP inhibitors can be developed. Combinatorial solid-phase library synthesis is finding wide applicability throughout the pharmaceutical industry and has begun to yield fruitful results in the area of PTP inhibitors.",
author = "Zhong-Yin Zhang",
year = "2010",
doi = "10.1016/B978-0-12-374145-5.00093-0",
language = "English",
isbn = "9780123741455",
volume = "2",
pages = "727--735",
booktitle = "Handbook of Cell Signaling, 2/e",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Inhibitors of protein tyrosine phosphatases

AU - Zhang, Zhong-Yin

PY - 2010

Y1 - 2010

N2 - Protein tyrosine phosphatases (PTPs) are a large family of enzymes whose structural diversity and complexity rival those of protein tyrosine kinases (PTKs). This chapter summarizes and updates what is currently known about PTP inhibitors. Both specific and non-specific small molecule competitive and reversible PTP inhibitors are discussed. In addition, some examples of covalent and time-dependent PTP inactivators are also presented. Although all PTPs share a common catalytic mechanism and catalyze the same biochemical reaction, the hydrolysis of phosphoamino acids, they have distinct (and often unique) biological functions in vivo. Genetics and biochemical studies indicate that PTPs are involved in a number of disease processes. In spite of the large number of PTPs identified to date, and the emerging roles played by PTPs in human diseases, a detailed understanding of the role played by PTPs in normal physiology and in pathogenic conditions has been hampered by the absence of PTP-specific agents. Such PTP specific inhibitors could potentially serve as useful tools in determining the physiological significance of protein tyrosine phosphorylation in complex cellular signal transduction pathways, and may constitute valuable therapeutics in the treatment of several human diseases. Significant differences exist within the active site and its immediate surroundings of various PTPs, such that selective, tight-binding PTP inhibitors can be developed. Combinatorial solid-phase library synthesis is finding wide applicability throughout the pharmaceutical industry and has begun to yield fruitful results in the area of PTP inhibitors.

AB - Protein tyrosine phosphatases (PTPs) are a large family of enzymes whose structural diversity and complexity rival those of protein tyrosine kinases (PTKs). This chapter summarizes and updates what is currently known about PTP inhibitors. Both specific and non-specific small molecule competitive and reversible PTP inhibitors are discussed. In addition, some examples of covalent and time-dependent PTP inactivators are also presented. Although all PTPs share a common catalytic mechanism and catalyze the same biochemical reaction, the hydrolysis of phosphoamino acids, they have distinct (and often unique) biological functions in vivo. Genetics and biochemical studies indicate that PTPs are involved in a number of disease processes. In spite of the large number of PTPs identified to date, and the emerging roles played by PTPs in human diseases, a detailed understanding of the role played by PTPs in normal physiology and in pathogenic conditions has been hampered by the absence of PTP-specific agents. Such PTP specific inhibitors could potentially serve as useful tools in determining the physiological significance of protein tyrosine phosphorylation in complex cellular signal transduction pathways, and may constitute valuable therapeutics in the treatment of several human diseases. Significant differences exist within the active site and its immediate surroundings of various PTPs, such that selective, tight-binding PTP inhibitors can be developed. Combinatorial solid-phase library synthesis is finding wide applicability throughout the pharmaceutical industry and has begun to yield fruitful results in the area of PTP inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=84882819874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882819874&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-374145-5.00093-0

DO - 10.1016/B978-0-12-374145-5.00093-0

M3 - Chapter

SN - 9780123741455

VL - 2

SP - 727

EP - 735

BT - Handbook of Cell Signaling, 2/e

PB - Elsevier Inc.

ER -